Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

The objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels.

Why It Was Studied

Intermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear.

Who Took Part

The study group was 27 women.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.

Participants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

The study was conducted at a clinical research unit.

What Was Measured

PubMed files the paper under topics including Adaptor Proteins, Signal Transducing, Bone Morphogenetic Proteins, Enzyme-Linked Immunosorbent Assay, Genetic Markers, Intercellular Signaling Peptides and Proteins, Osteocalcin and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 27 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.